SCHEMBL4580733

SCHEMBL4580733

O=C(O)c1ccc2c(Cl)ncc(-c3cccs3)c2n1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
TOP2A P11388 1/20 0.37
PIM1 P11309 1/20 0.37
PIM3 Q86V86 1/20 0.37
PLK3 Q9H4B4 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
PLAUR Q03405 1/20 0.36
GPR35 Q9HC97 1/20 0.36
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14266824 0.78 ALDH1A1 (0.57) KDM4EKMT2AMEN1MAPTRAB9A
SCHEMBL4580252 0.76 CCNC (0.48) KDM4EKMT2AMEN1PIM1PIM3
SCHEMBL14286999 0.75 MEN1 (0.39) KDM4EKMT2AMEN1RAB9A
SCHEMBL4580245 0.68 KDM4E (0.45) KDM4EKMT2AMEN1PIM1PIM3
SCHEMBL6234452 0.68 KDM4E (0.54) KDM4EKMT2AMEN1PIM1PIM3
SCHEMBL10722440 0.68 EGLN1 (0.56) KDM4EKMT2AMEN1PIM1PIM3
SCHEMBL31437889 0.65 PTPN1 (0.51) KDM4EKMT2AMEN1RXFP1
SCHEMBL2972148 0.65 KDM4E (0.63) KDM4EKMT2AMEN1PIM1PIM3
SCHEMBL1560087 0.64 KDM4E (0.53) KDM4EKMT2AMEN1PIM1PIM3
SCHEMBL7128444 0.64 PDE4A (0.40) KDM4EKMT2AMEN1PLAURMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed
EP-1773834-A2 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES Serenex, Inc. (US) 2007-04-18 EP disclosed
WO-2006017672-A2 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES SERENEX INC. (US) 2006-02-16 WO disclosed
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives SERENEX, INC. 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives CCNA1, FOXM1, CCNA2 KDM4E 3744/4885KMT2A 2613/4885MEN1 2217/4885
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives CCNA1, FOXM1, CCNA2 KDM4E 3744/4885KMT2A 2613/4885MEN1 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.